Mi a EQRx, Inc. (EQRX piaci tőkésítése)

EQRx, Inc. piaci tőkésítése (EQRX) $728.90M

EQRx, Inc. (EQRX) Árfolyamtörténet

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Év	Teljesítmény
2023	-10.70%
2022	-68.78%
2021	0.00%

Év

Teljesítmény

2023

-10.70%

2022

-68.78%

2021

0.00%

Vállalat	Részvényár	Változás 1év%	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$542.09	38.63%	US
Argenx SE ARGX.US	$1.03K	44.13%	NL
CSL Limited CSL.AX	$121.53	-12.70%	AU
Moderna, Inc. MRNA.US	$138.18	473.58%	US
Lonza Group AG LONN.SW	$759.27	7.20%	CH

Vállalat

Részvényár

Változás 1év%

Ország